PT  - JOURNAL ARTICLE
AU  - J Alvin
AU  - T McHorse
AU  - A Hoyumpa
AU  - M T Bush
AU  - S Schenker
TI  - The effect of liver disease in man on the disposition of phenobarbital.
DP  - 1975 Jan 01
TA  - Journal of Pharmacology and Experimental Therapeutics
PG  - 224--235
VI  - 192
IP  - 1
4099  - http://jpet.aspetjournals.org/content/192/1/224.short
4100  - http://jpet.aspetjournals.org/content/192/1/224.full
SO  - J Pharmacol Exp Ther1975 Jan 01; 192
AB  - The disposition of phenobarbital (PB) was studied in normal individuals and in patients with cirrhosis or acute viral hepatitis to determine 1) if there is significant impairment of PB metabolism in hepatic disease and 2) to what extent such abnormal disposition of the drug affects its disappearance from blood. The diagnosis of liver disease was based on characteristic clinical findings, biochemical liver "function" tests and liver biopsy when necessary. All individuals had normal renal function and were free of other drug and alcohol intake for at least 3 weeks. With radiotracer methodology, PB and its principal metabolites, p-hydroxyphenobarbital (PBOH) and conjugated PBOH (PBOC), were monitored in blood and urine for 5 days after a single dose of 14-C-PBadministered intraduodenally. PB blood half-life (T1/2) in the control group was 86 plus or minus 3 hours (S.E.). In cirrhotics the T1/2 was prolonged to 130 plus or minus 15 hours (P less than .001) and this was accompanied by a 50% reduction in urinary PBOC excretion (P less than .05). Urinary excretion of PB and PBOH was unaltered by cirrhosis. In patients with acute viral hepatitis, PB T1/2 was not significantly prolonged and urinary excretion of PB and its metabolites was in the normal range (P greater than .05). No PBOH and only traces of PBOC were detected in the blood of either control individuals or patients with liver disease. Urinary excretion of unchanged PB was an important elimination pathway of the drug in all groups. As a result of this, PB T1/2 in cirrhosis was only moderately prolonged.